An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
By Rudi Filapek-Vandyck
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
29M A1N ACE ACF (2) ACL AHX AMI AUB BGL CVV CWP EMR EVT FMG GNE HGO HLO IDX (2) IGO INA JIN (2) LOV MAD MVF NAN NEU NUZ OBM PDN PFP PRU RMD SCG SDV SFR SHL SKS SLX SOM TLX TYR WEB WGX
29M 29METALS LIMITED
Copper - Overnight Price: $0.34
rates ((29M)) as (4) -
29Metals achieved an interim earnings beat through what Jarden describes as a "surprise" inclusion of $54m in insurance proceeds, which accounted for the difference.
Ex-insurance proceeds, cash flow was negative at -$52m over the first half for an overall cash outflow of -$65m, with repayment of debt and leases of -$66m. Liquidity stood at around $202m at the end of June.
The miner retained 2025 guidance, and the analyst remains comfortable with production forecasts below management's guidance.
No change to Underweight rating and 30c target price.
This report was published on August 26, 2025.
Target price is $0.30 Current Price is $0.34 Difference: minus $0.04 .
If 29M meets the Jarden target it will return approximately minus 12% .
Current consensus price target is $0.25, suggesting downside of -27.2%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 3.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 10.30.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 0.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 42.5.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 21.25.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -0.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
A1N ARN MEDIA LIMITED
Print, Radio & TV - Overnight Price: $0.51
rates ((A1N)) as (3) -
Canaccord Genuity describes ARN Media's 1H25 result as complicated, with the Hong Kong OOH (Cody Outdoor) business reclassified as discontinued (pending disposal) and the agency business Emotiv sold in May 2025.
The continuing Audio business materially underperformed peers, particularly in Metro and Regional Radio, despite digital growth. Revenue of $142.3m was down -7% y/y and missed the broker's forecast by -7%.
Gross margins improved and cost savings were substantial, but the broker trimmed FY25 EBITDA forecast by -14%. Revenue forecast was lowered by -7%.
Rating downgraded to Hold from Buy. Target cut to 50c from 95c.
This report was published on August 28, 2025.
Target price is $0.50 Current Price is $0.51 Difference: minus $0.005 .
If A1N meets the Canaccord Genuity target it will return approximately minus 1% .
Current consensus price target is $0.49, suggesting downside of -3.0%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 3.00 cents and EPS of 5.30 cents.
At the last closing share price the estimated dividend yield is 5.94%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.53.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 4.9, implying annual growth of 288.9%.
Current consensus DPS estimate is 2.3, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 10.3.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 5.00 cents and EPS of 8.50 cents.
At the last closing share price the estimated dividend yield is 9.90%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.94.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.5, implying annual growth of 12.2%.
Current consensus DPS estimate is 2.3, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 9.2.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ACE ACUSENSUS LIMITED
Transportation & Logistics - Overnight Price: $1.00
rates ((ACE)) as (1) -
Wilsons highlights FY25 was a strong year for Acusensus, marked by contract wins across every tender for new enforcement services in Australia and New Zealand. The company also invested in growth by spending -$13m on PP&E.
Revenue rose 20% y/y to $59.4m, meeting the broker's forecast. Gross margins fell -119bps to 44.9% and the company expects it to decline further as speed enforcement cameras make up a larger proportion of revenue.
EBITDA missed the broker's estimate due to higher-than-expected headcount and spending to support growth in the UK and the US.
FY26 revenue guidance midpoint was 5% above consensus, leading to a 5-7% lift in the broker's revenue forecasts for FY26-27. EBITDA forecasts, however, declined due to growth-supporting expenses.
Overweight. Target trimmed to $1.21 from $1.23.
This report was published on August 27, 2025.
Target price is $1.21 Current Price is $1.00 Difference: $0.21
If ACE meets the Wilsons target it will return approximately 21% .
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 62.50.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 45.45.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ACF ACROW LIMITED
Building Products & Services - Overnight Price: $1.03
rates ((ACF)) as (1) -
Acrow's FY25 revenue rose by 23% and earnings (EBITDA) lifted by 8% year-on-year, broadly in line with guidance and consensus, highlights Moelis.
Industrial Access Services expanded rapidly, observes the broker, and now accounts for 50% of group revenue, with hire contracts up 27% to $98.2m. FY25 revenue grew 83% to $132m, driven by organic growth and the Brand and Above acquisition, explains the analyst.
Net debt rose to $123m, equal to 1.8 times earnings, with management targeting reduction in FY26 as capex falls to -$27m.
The broker lowers its FY26, FY27, and FY28 EPS forecasts by -14%, -10%, and -4%, respectively, reflecting weaker expectations for Formwork. Moelis reduces its target price to $1.32 from $1.44 and retains a Buy rating.
This report was published on August 26, 2025.
Target price is $1.32 Current Price is $1.03 Difference: $0.285
If ACF meets the Moelis target it will return approximately 28% .
Current consensus price target is $1.31, suggesting upside of 26.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 5.70 cents and EPS of 11.30 cents.
At the last closing share price the estimated dividend yield is 5.51%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.16.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.6, implying annual growth of 53.2%.
Current consensus DPS estimate is 6.0, implying a prospective dividend yield of 5.8%.
Current consensus EPS estimate suggests the PER is 8.9.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 6.30 cents and EPS of 12.70 cents.
At the last closing share price the estimated dividend yield is 6.09%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.15.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.4, implying annual growth of 15.5%.
Current consensus DPS estimate is 6.5, implying a prospective dividend yield of 6.3%.
Current consensus EPS estimate suggests the PER is 7.7.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
rates ((ACF)) as (1) -
Acrow's FY25 earnings (EBITDA) of $80.2m came in at the low end of guidance, notes Petra Capital, with formwork revenue weaker due to project delays and softer gross margins in the second half.
Debt levels rose and cash flow declined, while Industrial Access revenue doubled and continued to consolidate acquisitions, highlights the analyst.
Petra Capital expects FY26 will remain challenging, with formwork demand subdued in the first half. Industrial Access revenue is forecast to reach around $200m, driving 23.7% revenue growth and 5.8% earnings growth.
The broker's forecasts now include the Brisbane Olympics, with activity expected from 2H27 through 1H31. The project could deliver $76-152m of sector revenue, providing meaningful upside for formwork.
The analyst highlights a pipeline of $217.5m and sees earnings stabilising as projects are delivered. Moelis cuts its target price to $1.68 from $1.80 and retains a Buy rating.
This report was published on August 27, 2025.
Target price is $1.68 Current Price is $1.03 Difference: $0.645
If ACF meets the Petra Capital target it will return approximately 62% .
Current consensus price target is $1.31, suggesting upside of 26.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 5.60 cents and EPS of 11.20 cents.
At the last closing share price the estimated dividend yield is 5.41%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.24.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.6, implying annual growth of 53.2%.
Current consensus DPS estimate is 6.0, implying a prospective dividend yield of 5.8%.
Current consensus EPS estimate suggests the PER is 8.9.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 7.80 cents and EPS of 15.50 cents.
At the last closing share price the estimated dividend yield is 7.54%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.68.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.4, implying annual growth of 15.5%.
Current consensus DPS estimate is 6.5, implying a prospective dividend yield of 6.3%.
Current consensus EPS estimate suggests the PER is 7.7.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ACL AUSTRALIAN CLINICAL LABS LIMITED
Healthcare services - Overnight Price: $2.67
rates ((ACL)) as (1) -
Wilsons has an Overweight rating and $3.85 target price on Australian Clinical Labs.
The company recorded a 6% y/y lift in group revenue in FY25, with underlying net profit of $34m beating the broker's forecast by 3%.
The broker noted prudent cost management, particularly in labour, alongside targeted, profitable revenue growth resulted in margins outperforming its FY25 expectations.
FY26 revenue guidance of $760-780m implies a 4% increase at the midpoint but missed the broker's and consensus forecast by -3%. The broker sees this as a near-term headwind but expects company-wide initiatives to drive meaningful margin lift in FY27, and double-digit margins by FY28.
This report was published on August 27, 2025.
Target price is $3.85 Current Price is $2.67 Difference: $1.18
If ACL meets the Wilsons target it will return approximately 44% .
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 11.40 cents and EPS of 19.00 cents.
At the last closing share price the estimated dividend yield is 4.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.05.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 13.20 cents and EPS of 22.00 cents.
At the last closing share price the estimated dividend yield is 4.94%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.14.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AHX APIAM ANIMAL HEALTH LIMITED
Healthcare services - Overnight Price: $0.80
rates ((AHX)) as (3) -
Canaccord Genuity assesses Apiam Animal Health's FY25 result as solid, with underlying EBITDA beating its forecast by 9% and net profit by 24%.
Intensive Animal Vet Services was the revenue driver, up 13% y/y, offsetting the -2.2% y/y decline in Clinical Vet Services. Strong cost control was the highlight, with opex down -1% y/y, and $1.5m of cost reductions made in June/July.
With Intensive Animal Vet Services growing strongly and cost initiatives set to flow through in FY26, the broker believes the company is positioned well for both margin recovery and future scaling.
FY26 EBITDA forecast lifted by 8% and FY27 by 5.5%.
Hold. Target trimmed to 87c from 88c following final dividend of 1c.
This report was published on August 28, 2025.
Target price is $0.87 Current Price is $0.80 Difference: $0.07
If AHX meets the Canaccord Genuity target it will return approximately 9% .
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 2.00 cents and EPS of 5.00 cents.
At the last closing share price the estimated dividend yield is 2.50%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.00.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 2.00 cents and EPS of 5.00 cents.
At the last closing share price the estimated dividend yield is 2.50%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.00.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AMI AURELIA METALS LIMITED
Gold & Silver - Overnight Price: $0.22
rates ((AMI)) as (1) -
Aurelia Metals reported FY25 revenue of $343.5m, ahead of Moelis’ $339.3m forecast, with earnings (EBITDA) of $111.5m versus $106.5m.
Profit of $45.4m also beat the broker’s $34.1m forecast, driven by around -$9m lower D&A, while reported profit was $48.9m. Operating cash flow (OCF) of $129.7m also came in above expectations of $125.6m.
At first glance, the stronger result was mainly revenue-driven, explains the analyst, with finance costs in line. Lower-than-expected D&A provided additional support to earnings and may have ongoing benefits if sustained.
The result may restore confidence after recent medium-term outlook downgrades, suggests Moelis.
Buy rating. Unchanged target price of 31c.
This report was published on August 26, 2025.
Target price is $0.31 Current Price is $0.22 Difference: $0.09
If AMI meets the Moelis target it will return approximately 41% .
Current consensus price target is $0.33, suggesting upside of 50.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.57.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 2.4, implying annual growth of -17.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 9.2.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.48.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1.7, implying annual growth of -29.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 12.9.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AUB AUB GROUP LIMITED
Insurance - Overnight Price: $34.97
rates ((AUB)) as (2) -
A surprising international result helped AUB Group achieve a solid to better-than-expected FY25 earnings report. Underlying net profit after tax grew 17.1%.
Management's FY26 guidance is considered conservative, with potential for positive margin upside. The analyst's FY30 margin forecasts are around 100bps to 800bps below the company's ambitions, leaving scope for beats to expectations.
Jarden lowers its EPS forecasts by -3.8% for FY26 and -3.2% for FY27.
Overweight retained. Target slips to $37.20 from $38.25.
This report was published on August 27, 2025.
Target price is $37.20 Current Price is $34.97 Difference: $2.23
If AUB meets the Jarden target it will return approximately 6% .
Current consensus price target is $37.27, suggesting upside of 6.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 105.00 cents and EPS of 190.70 cents.
At the last closing share price the estimated dividend yield is 3.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.34.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 191.4, implying annual growth of 23.9%.
Current consensus DPS estimate is 104.4, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 18.4.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 117.00 cents and EPS of 213.30 cents.
At the last closing share price the estimated dividend yield is 3.35%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.39.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 205.1, implying annual growth of 7.2%.
Current consensus DPS estimate is 111.5, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 17.1.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BGL BELLEVUE GOLD LIMITED
Gold & Silver - Overnight Price: $0.89
rates ((BGL)) as (1) -
Bellevue Gold's FY25 revenue of $506m beat Canaccord Genuity's forecast by 3% but was in line with the consensus. Underlying EBITDA beat the broker and the consensus forecasts by 11% and 6%, respectively.
Net profit, however, missed because of costs with hedge closing.
FY26 guidance was announced before, and the broker already adjusted the production forecast to align with it. This time, the broker lifted FY26 cost forecast by 3% to $2,751, but expects it to be weighted towards 2H.
Speculative Buy. Target unchanged at $1.65.
This report was published on August 28, 2025.
Target price is $1.65 Current Price is $0.89 Difference: $0.76
If BGL meets the Canaccord Genuity target it will return approximately 85% .
Current consensus price target is $1.15, suggesting upside of 27.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 9.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.89.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 9.7, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 9.3.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 14.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.36.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.8, implying annual growth of -40.2%.
Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 2.2%.
Current consensus EPS estimate suggests the PER is 15.5.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CVV CARAVEL MINERALS LIMITED
Copper - Overnight Price: $0.15
rates ((CVV)) as (1) -
Caravel Minerals appointed Primero Group, a subsidiary of NRW Holdings ((NWH)) as EPCM for the Caravel copper project. Canaccord Genuity notes this aligns with its forecast for a Definitive Feasibility Study completion by mid-2026.
The broker expects project financing and FID in 2H of 2026, and construction to start in early 2027. Commissioning and ramp-up are modelled from 2H 2028.
The broker reminds the Caravel project is one of the largest, if not the largest, undeveloped copper projects in Australia.
Speculative Buy. Target price 62c.
This report was published on August 28, 2025.
Target price is $0.62 Current Price is $0.15 Difference: $0.47
If CVV meets the Canaccord Genuity target it will return approximately 313% .
The company's fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CWP CEDAR WOODS PROPERTIES LIMITED
Infra & Property Developers - Overnight Price: $7.41
rates ((CWP)) as (1) -
FY25 EPS for Cedar Woods Properties of 58.4c came in ahead of Moelis’ 56.9c estimate. Presales reached a record $660m, highlights the analyst, underpinning FY26 guidance for profit growth of at least 10%.
Margins expanded to 28% from 25% in FY24, supported by strong price growth across key markets, explains the broker.
Moelis notes 1,125 lot settlements in FY25, with a 6% increase expected in FY26. Queensland and WA are driving growth, explains the broker, South Australia remains steady, and Victoria is expected to recover on affordability and population growth.
The broker upgrades its medium-term EPS forecasts, highlighting capacity to harvest a low-cost landbank into supply-constrained markets. It's noted inventory covers three years of sales with additional stock beyond that period, ensuring strong visibility.
Moelis raises its target price to $8.36 from $7.63 and maintains a Buy rating.
This report was published on August 27, 2025.
Target price is $8.36 Current Price is $7.41 Difference: $0.95
If CWP meets the Moelis target it will return approximately 13% .
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 32.50 cents and EPS of 64.90 cents.
At the last closing share price the estimated dividend yield is 4.39%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.42.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 36.50 cents and EPS of 73.40 cents.
At the last closing share price the estimated dividend yield is 4.93%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.10.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EMR EMERALD RESOURCES NL
Gold & Silver - Overnight Price: $4.01
rates ((EMR)) as (1) -
Emerald Resources' FY25 reported EBITDA of $204m fell short of Canaccord Genuity's forecast of $211m and the consensus of $219m due to royalty and selling costs.
Reported net profit was a bigger miss, with the $88m outcome compared with the broker's $116m estimate on higher D&A and tax.
FY26 guidance was provided earlier and retained at 105-120koz, and no specific FY26 cost guidance was provided, though the company did flag 1H26 cost in US$900-10000/oz range.
The broker made minor revisions to depreciation estimates. Buy. Target unchanged at $5.5.
This report was published on August 28, 2025.
Target price is $5.50 Current Price is $4.01 Difference: $1.49
If EMR meets the Canaccord Genuity target it will return approximately 37% .
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 36.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.14.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 8.00 cents and EPS of 44.00 cents.
At the last closing share price the estimated dividend yield is 2.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.11.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EVT EVT LIMITED
Travel, Leisure & Tourism - Overnight Price: $13.83
rates ((EVT)) as (2) -
Jarden downgrades EVT Ltd to Overweight from Buy post FY25 net profit after tax, which came in lower than anticipated but beat consensus by 6% when tax-adjusted and by 11% after cyclone impacts.
Cinemas disappointed, notably in Germany, down around -5%, while Australia fell -4%.
The analyst lowers earnings (EBITDA) forecasts by around -3% to -11% for FY26-FY28, from revenue downgrades of -3% to -4%, with more conservative recovery assumptions adopted.
Target price slips to $16.34 from $18.70.
This report was published on August 26, 2025.
Target price is $16.34 Current Price is $13.83 Difference: $2.51
If EVT meets the Jarden target it will return approximately 18% .
Current consensus price target is $17.75, suggesting upside of 29.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 EPS of 41.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 33.73.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 44.0, implying annual growth of 114.1%.
Current consensus DPS estimate is 36.4, implying a prospective dividend yield of 2.7%.
Current consensus EPS estimate suggests the PER is 31.2.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 47.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 29.18.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 54.8, implying annual growth of 24.5%.
Current consensus DPS estimate is 42.6, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 25.0.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FMG FORTESCUE LIMITED
Iron Ore - Overnight Price: $18.40
rates ((FMG)) as (4) -
Jarden downgrades Fortescue to Underweight from Neutral due to the stock's recent outperformance and valuation grounds.
The miner achieved what the analyst considers "operational excellence" in FY25, with record shipments and industry-leading costs. Momentum has been retained into FY26.
The analyst raises capital investment forecasts by 2%-4% for FY27-FY30, with only slight changes to other operating financial forecasts, resulting in an impact on EPS estimates, down -3% for FY26 and -2% for FY27.
Target slips to $16 from $16.25.
This report was published on August 27, 2025.
Target price is $16.00 Current Price is $18.40 Difference: minus $2.4 .
If FMG meets the Jarden target it will return approximately minus 13% .
Current consensus price target is $17.99, suggesting downside of -1.4%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 82.00 cents and EPS of 140.60 cents.
At the last closing share price the estimated dividend yield is 4.46%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.09.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 137.7, implying annual growth of N/A.
Current consensus DPS estimate is 91.0, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 13.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 63.56 cents and EPS of 86.34 cents.
At the last closing share price the estimated dividend yield is 3.45%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.31.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 106.8, implying annual growth of -22.4%.
Current consensus DPS estimate is 65.0, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 17.1.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GNE GENESIS ENERGY LIMITED
Infrastructure & Utilities - Overnight Price: $2.12
rates ((GNE)) as (1) -
Genesis Energy's FY25 results saw normalised earnings of NZ$470m, slightly higher than guidance of NZ$460m, Jarden observes.
FY26 guidance, however, surprised to the downside due to a pick-up in digital spending, Kupe costs, and hydro. Guidance sits at NZ$430m-NZ$460m, with the timing of the opex coming as the surprise, not the project costs.
Jarden lowers its earnings (EBITDA) forecast to NZ$603m from NZ$630m, versus the company's guidance at NZ$550m.
Target slips to NZ$2.93 from NZ$3. No change to Buy rating.
This report was published on August 26, 2025.
Current Price is $2.12. Target price not assessed.
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 13.51 cents and EPS of 7.49 cents.
At the last closing share price the estimated dividend yield is 6.37%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 28.32.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 13.88 cents and EPS of 10.77 cents.
At the last closing share price the estimated dividend yield is 6.54%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.68.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HGO HILLGROVE RESOURCES LIMITED
Copper - Overnight Price: $0.04
rates ((HGO)) as (1) -
Hillgrove Resources' first-half FY25 result was broadly in line with the Moelis forecast at the earnings (EBITDA) level, with $14.2m reported against the broker's $16m forecast. The analyst highlights a -$1.7m inventory movement was treated as a cost.
Revenue was $81.3m, matching the broker's forecast, while profit of $3.6m beat expectations due to lower-than-expected D&A of -$9m versus the broker’s -$21m estimate. Operating cash flow (OCF) was $12.4m compared with $9.8m forecast.
Near-term production volatility continues to weigh on investor confidence, suggests the analyst. however, it's thought management execution and exploration success underpin long-term potential.
Buy rating with an unchanged 6c target price.
This report was published on August 26, 2025.
Target price is $0.06 Current Price is $0.04 Difference: $0.02
If HGO meets the Moelis target it will return approximately 50% .
The company's fiscal year ends in December.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.00.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 3.33.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HLO HELLOWORLD TRAVEL LIMITED
Travel, Leisure & Tourism - Overnight Price: $1.79
rates ((HLO)) as (2) -
Helloworld Travel reported in-line FY25 results, with earnings (EBITDA) at the midpoint of guidance at $60.6m, which was a decline of -8.6% on the prior year despite "good" margins, Jarden comments.
TTV fell -8.6% on lower traveller numbers and a change in mix to mid-haul from long-haul, with airfare deflation.
Management expects an improved performance for FY26. Air departure bookings are already up 11% year-to-date, with 15 new stores planned.
Jarden lifts its EPS forecasts by 6.5% for FY26 and 2% for FY27. No change to Overweight rating and $2.80 target price. Analyst coverage is transferred.
This report was published on August 26, 2025.
Target price is $2.80 Current Price is $1.79 Difference: $1.01
If HLO meets the Jarden target it will return approximately 56% .
Current consensus price target is $2.24, suggesting upside of 24.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 EPS of 17.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.23.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 18.2, implying annual growth of 0.6%.
Current consensus DPS estimate is 11.3, implying a prospective dividend yield of 6.3%.
Current consensus EPS estimate suggests the PER is 9.9.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 18.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.57.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 18.4, implying annual growth of 1.1%.
Current consensus DPS estimate is 11.7, implying a prospective dividend yield of 6.5%.
Current consensus EPS estimate suggests the PER is 9.8.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IDX INTEGRAL DIAGNOSTICS LIMITED
Healthcare services - Overnight Price: $2.88
rates ((IDX)) as (1) -
Integral Diagnostics reported better-than-expected FY25 earnings, with net profit after tax assisted by lower depreciation, according to Jarden.
The outlook for FY26 relies on MRI deregulation, the National Lung Screening Program, the GP Bulk Billing program, as well as synergy capture and other factors, including slowing capex to -$45m-$55m from around -$65m.
Positively, labour costs have slowed into FY26, but any impacts will take time, commentary highlights, as will the spread of MRI deregulation benefits.
Jarden lowers its EPS forecasts by -7.3% for FY26 and -5.4% for FY27. Buy retained. Target falls to $3.41 from $3.45.
This report was published on August 27, 2025.
Target price is $3.41 Current Price is $2.88 Difference: $0.53
If IDX meets the Jarden target it will return approximately 18% .
Current consensus price target is $3.35, suggesting upside of 15.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 9.30 cents and EPS of 14.20 cents.
At the last closing share price the estimated dividend yield is 3.23%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.28.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.2, implying annual growth of 768.4%.
Current consensus DPS estimate is 8.7, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 21.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 12.00 cents and EPS of 18.30 cents.
At the last closing share price the estimated dividend yield is 4.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.74.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 16.0, implying annual growth of 21.2%.
Current consensus DPS estimate is 10.1, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 18.1.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
rates ((IDX)) as (3) -
Wilsons notes Integral Diagnostics' FY25 revenue rose 33% to $628m, missing its forecast by -1%. Revenue excluding Capitol Health grew only 7% to $501m, indicating organic growth lagged system growth.
EBITDA was up 37% to $127m, beating the broker's forecast by 4%, and net profit was ahead by 17%. The broker notes the 2H results drove the outperformance.
The company didn't provide quantitative guidance but highlighted expectations for revenue growth and expansion in underlying EBITDA margin over time.
The broker revised forecasts to incorporate additional synergies from the merger and lifted group margin profile, resulting in a 10-21% increase in underlying EPS forecasts for FY26-27.
Target increases to $3.00 from $2.75. Rating downgraded to Market Weight from Overweight.
This report was published on August 27, 2025.
Target price is $3.00 Current Price is $2.88 Difference: $0.12
If IDX meets the Wilsons target it will return approximately 4% .
Current consensus price target is $3.35, suggesting upside of 15.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 8.50 cents and EPS of 13.50 cents.
At the last closing share price the estimated dividend yield is 2.95%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.33.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.2, implying annual growth of 768.4%.
Current consensus DPS estimate is 8.7, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 21.9.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 9.50 cents and EPS of 15.20 cents.
At the last closing share price the estimated dividend yield is 3.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.95.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 16.0, implying annual growth of 21.2%.
Current consensus DPS estimate is 10.1, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 18.1.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IGO IGO LIMITED
Nickel - Overnight Price: $4.97
rates ((IGO)) as (3) -
IGO Ltd's FY25 EBITDA came in at -$43m vs pre-reported $14m, and unsurprisingly, missed both Canaccord Genuity and the consensus forecasts. The driver was a $58m increase in nickel rehabilitation provisions.
That flowed to the net profit line and missed expectations. The broker notes the share of loss from TLEA was -$642m, a sharp reversal from $553m profit received in FY24.
Net debt is now $75m after excluding $280m cash from the $355m debt position. While the result was heavily impacted by impairments and provisions, the broker reckons the near-term earnings profile is clouded too.
On the bright side, the lithium market is buoyant. No change to forecasts.
Hold. Target rises to $5.00 from $4.60.
This report was published on August 28, 2025.
Target price is $5.00 Current Price is $4.97 Difference: $0.03
If IGO meets the Canaccord Genuity target it will return approximately 1% .
Current consensus price target is $4.67, suggesting downside of -4.4%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 5.00 cents and EPS of 10.00 cents.
At the last closing share price the estimated dividend yield is 1.01%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 49.70.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 4.1, implying annual growth of N/A.
Current consensus DPS estimate is 2.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 119.0.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 10.00 cents and EPS of 26.00 cents.
At the last closing share price the estimated dividend yield is 2.01%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.12.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.3, implying annual growth of 322.0%.
Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 28.2.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
INA INGENIA COMMUNITIES GROUP
Aged Care & Seniors - Overnight Price: $5.75
rates ((INA)) as (2) -
Jarden retains an Overweight rating on Ingenia Communities and lifts the target price to $7.10 from $6.50, post what is considered management continuing to deliver on strategy with robust underlying profit growth in FY25.
FY26 guidance also came in better than anticipated at 32.5c-34c, with the analyst believing there is further upside potential if market conditions remain strong.
Jarden raises its funds from operations forecasts by 5% for FY26, while FY27 is left unchanged.
This report was published on August 26, 2025.
Target price is $7.10 Current Price is $5.75 Difference: $1.35
If INA meets the Jarden target it will return approximately 23% .
Current consensus price target is $6.26, suggesting upside of 9.2%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 10.10 cents and EPS of 33.90 cents.
At the last closing share price the estimated dividend yield is 1.76%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.96.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 32.6, implying annual growth of 3.5%.
Current consensus DPS estimate is 9.8, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 17.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 10.60 cents and EPS of 37.20 cents.
At the last closing share price the estimated dividend yield is 1.84%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.46.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 37.0, implying annual growth of 13.5%.
Current consensus DPS estimate is 10.1, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 15.5.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JIN JUMBO INTERACTIVE LIMITED
Gaming - Overnight Price: $11.73
rates ((JIN)) as (1) -
Jarden highlights an FY25 earnings beat from Jumbo Interactive and, like its peer The Lottery Corporation ((TLC)), the company performed well considering the soft jackpot activity. Results were boosted by higher digital penetration and robust cost management.
FY26 guidance seems conservative, with management inclined to invest more in marketing and abate market share loss since it has been regained. Marketing spend rises to 3-4% of TTV from 1.5-2%.
Jackpot activity is also expected to trend back to more normal levels. Jarden tweaks EPS forecasts by -0.1% for FY26-FY29.
Buy rating unchanged. Target slips to $13.20 from $13.40.
This report was published on August 26, 2025.
Target price is $13.20 Current Price is $11.73 Difference: $1.47
If JIN meets the Jarden target it will return approximately 13% .
Current consensus price target is $12.94, suggesting upside of 13.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 54.70 cents and EPS of 74.60 cents.
At the last closing share price the estimated dividend yield is 4.66%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.72.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 71.5, implying annual growth of 11.5%.
Current consensus DPS estimate is 54.5, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 16.0.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 87.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.36.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 80.9, implying annual growth of 13.1%.
Current consensus DPS estimate is 63.1, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 14.2.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
rates ((JIN)) as (1) -
Wilsons observes Jumbo Interactive posted a solid earnings beat in FY25, with growth across all three divisions (Lottery Retailing, SaaS, Managed Services). EBITDA of $68.3m beat the broker's forecast by 1% and net profit was ahead by 3%.
While the disappointment was the lower FY26 EBITDA guidance of 46-50% vs the FY25 range of 51-53% due to higher marketing costs, the broker is seeing it as a strategic investment.
Importantly, the broker is optimistic about multiple growth levers in FY26, including Powerball price increases, improved Lottery Retailing product mix, SaaS reseller agreements, and Managed Services expansion.
FY26-28 EBITDA forecasts trimmed by 4-6% due to higher marketing costs.
Overweight. Target cut to $13.99 from $14.38
This report was published on August 27, 2025.
Target price is $13.99 Current Price is $11.73 Difference: $2.26
If JIN meets the Wilsons target it will return approximately 19% .
Current consensus price target is $12.94, suggesting upside of 13.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 52.40 cents and EPS of 69.90 cents.
At the last closing share price the estimated dividend yield is 4.47%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.78.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 71.5, implying annual growth of 11.5%.
Current consensus DPS estimate is 54.5, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 16.0.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 58.90 cents and EPS of 78.50 cents.
At the last closing share price the estimated dividend yield is 5.02%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.94.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 80.9, implying annual growth of 13.1%.
Current consensus DPS estimate is 63.1, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 14.2.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
LOV LOVISA HOLDINGS LIMITED
Retailing - Overnight Price: $41.54
rates ((LOV)) as (3) -
Canaccord Genuity reiterates Lovisa Holdings' gross margin execution is outstanding, with sourcing/pricing discipline delivering powerful operating leverage. FY25 gross margin came at 82% in line with the broker's forecast, and up 20bps vs consensus.
Elevated cost of doing business, particularly in 2H25, weighed on EBIT margins despite strong revenue growth. Sales growth accelerated towards the end of FY25, with 2H25 registering 20% y/y growth vs 9% in 1H.
Store rollouts accelerated in 2H25, and FY25 saw net store growth of 131. In the first 8 weeks of FY26, store counts increased by a net 10, taking the network total to 1,041, with sales momentum also picking up pace.
The broker lifted FY26 EBITDA by 5% and FY27 by 2%.
Hold. Target rises to $37.60 from $28.70.
This report was published on August 28, 2025.
Target price is $37.60 Current Price is $41.54 Difference: minus $3.94 .
If LOV meets the Canaccord Genuity target it will return approximately minus 9% .
Current consensus price target is $38.70, suggesting downside of -5.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 89.30 cents and EPS of 94.00 cents.
At the last closing share price the estimated dividend yield is 2.15%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 44.19.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 101.0, implying annual growth of 29.3%.
Current consensus DPS estimate is 87.7, implying a prospective dividend yield of 2.1%.
Current consensus EPS estimate suggests the PER is 40.7.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 97.30 cents and EPS of 108.00 cents.
At the last closing share price the estimated dividend yield is 2.34%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 38.46.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 120.2, implying annual growth of 19.0%.
Current consensus DPS estimate is 100.8, implying a prospective dividend yield of 2.5%.
Current consensus EPS estimate suggests the PER is 34.2.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MAD MADER GROUP LIMITED
Mining Sector Contracting - Overnight Price: $8.37
rates ((MAD)) as (3) -
Mader Group's FY25 results were in line with guidance and forecasts by Moelis, with revenue of $870m and profit of $57m.
Australia grew 17% on strong contributions from infrastructure, rail, and road, highlights the broker, while North America improved in the second half with 8% revenue growth and stable margins.
The group profit margin expanded to 6.6%, and a fully franked 4c dividend was declared.
Net debt fell to $8m from $23.2m in December, with the business on track for a net cash position within twelve months, suggests the analyst. Cash conversion of 101% supported $42.7m in operating cash flow, with cash of $24m at June end.
FY26 guidance targets at least $1bn in revenue and $65m profit, consistent with the five-year strategic plan, observes Moelis.
Moelis raises its target price to $8.29 from $6.83 reflecting stronger domestic momentum and higher utilisation of a growing workforce. and downgrades to a Hold rating from Buy.
This report was published on August 26, 2025.
Target price is $8.29 Current Price is $8.37 Difference: minus $0.08 .
If MAD meets the Moelis target it will return approximately minus 1% .
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 8.80 cents and EPS of 31.90 cents.
At the last closing share price the estimated dividend yield is 1.05%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 26.24.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 8.80 cents and EPS of 37.20 cents.
At the last closing share price the estimated dividend yield is 1.05%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 22.50.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MVF MONASH IVF GROUP LIMITED
Healthcare services - Overnight Price: $0.71
rates ((MVF)) as (3) -
Wilsons downgraded Monash IVF to Market Weight from Overweight and cut the target price to $0.72, a -20% discount to discounted cash flow, from $1.25.
The combination of patient volume decline, market share losses, weak pricing power, and negative operating leverage leaves the outlook too uncertain for a positive recommendation, the broker notes.
M&A potential at depressed multiples is a reason to hold, but near-term earnings risk dominates, the broker adds.
FY25 revenue rose 7% y/y, meeting the broker's forecast but missing the consensus. The company is guiding to net profit of $20-23m in FY26, which implies -21.5% lower y/y.
The broker downgraded its net profit forecast by -29% y/y to $19.6m.
This report was published on August 25, 2025.
Target price is $0.72 Current Price is $0.71 Difference: $0.01
If MVF meets the Wilsons target it will return approximately 1% .
Current consensus price target is $0.92, suggesting upside of 27.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 3.50 cents and EPS of 5.00 cents.
At the last closing share price the estimated dividend yield is 4.93%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.20.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.3, implying annual growth of -17.4%.
Current consensus DPS estimate is 2.9, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 13.6.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 3.70 cents and EPS of 5.30 cents.
At the last closing share price the estimated dividend yield is 5.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.40.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.9, implying annual growth of 11.3%.
Current consensus DPS estimate is 3.6, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 12.2.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NAN NANOSONICS LIMITED
Medical Equipment & Devices - Overnight Price: $4.29
rates ((NAN)) as (1) -
Nanosonics' FY25 group revenue rose 17% to $199m, beating Wilsons' forecast by 2%. Operating cash flow was a solid beat, pushing the cash position to $162m.
FY26 revenue guidance range is $215-223m, and assumes flat product sales at the bottom end and price increases. The broker is forecasting $215.7m revenue, estimating 2-4% lift in Trophon sales, offsetting the delay in Coris revenue.
The implied EBIT guidance is $14.4-20.7m, and the broker is forecasting $15.5m, leaving scope for upgrades.
Overall, the broker reckons Trophon EBIT momentum, combined with the SaaS layer from T2+/T3, underpins confidence in accelerating medium-term earnings.
Overweight. Target rises to $6.39 from $6.00.
This report was published on August 27, 2025.
Target price is $6.39 Current Price is $4.29 Difference: $2.1
If NAN meets the Wilsons target it will return approximately 49% .
Current consensus price target is $4.68, suggesting upside of 8.7%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 78.00.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.5, implying annual growth of 10.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 57.3.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 0.00 cents and EPS of 7.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 55.71.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 9.3, implying annual growth of 24.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 46.2.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NEU NEUREN PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $19.61
rates ((NEU)) as (1) -
Neuren Pharmaceuticals' 1H25 royalties revenue fell -5% short of Wilsons' forecast, EBITDA missed but net profit was ahead. The company finished 1H26 with $300m net cash, up 26% y/y.
The broker expects strong 2H momentum, supported by field-force expansion and direct-to-consumer marketing. Royalty outlook remains attractive, while the recent initiation of the PMS Phase III study for NNZ-2591 sets up a transformational data readout in 2H27.
The broker sees significant optionality from additional indications, leveraging paediatric rare disease designations and regulatory incentives.
No milestone receipt is expected in 2H, but in FY26, the broker is factoring in US$35m receipt triggered by the first Daybue sales outside the US. A second milestone of US$50m is expected in FY28.
Overweight. Target unchanged at $26.50.
This report was published on August 28, 2025.
Target price is $26.50 Current Price is $19.61 Difference: $6.89
If NEU meets the Wilsons target it will return approximately 35% .
Current consensus price target is $24.70, suggesting upside of 27.6%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 20.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 94.73.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 14.4, implying annual growth of -87.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 134.4.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 32.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 60.34.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 32.3, implying annual growth of 124.3%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 59.9.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NUZ NEURIZON THERAPEUTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $0.15
rates ((NUZ)) as (1) -
Moelis highlights Neurizon Therapeutics is approaching a key milestone with the FDA decision on its IND for NUZ-001 expected by October 3.
The deferral of the decision relates to a heavy workload at the FDA, not the quality of management's response, highlights the broker.
This decision will determine whether dosing can commence in the Healey ALS trial, a study designed to accelerate the development of potential treatments for amyotrophic lateral sclerosis (ALS).
This trial is considered by Petra Capital an important step toward advancing NUZ-001 as a potential disease-modifying therapy.
Management has confirmed readiness to begin dosing in the December quarter if approval is granted.
A decision could even come in late September, highlights Petra Capital, with a recent ALS IND clearance for Coya Therapeutics providing a positive precedent.
Neurizon Therapeutics' FY25 net loss of -$16.6m was in line with forecasts, while pro forma cash of $5.7m, including a loan against the R&D tax rebate, is expected to fund operations through the IND inflexion point. An R&D rebate of $4.1m is expected in 1H26.
The broker's target price rises to 52c from 50c. Buy rating is maintained.
This report was published on August 27, 2025.
Target price is $0.52 Current Price is $0.15 Difference: $0.37
If NUZ meets the Petra Capital target it will return approximately 247% .
The company's fiscal year ends in June.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
OBM ORA BANDA MINING LIMITED
Gold & Silver - Overnight Price: $0.91
rates ((OBM)) as (1) -
Ora Banda Mining reported FY25 earnings (EBITDA) of $184.6m were ahead of the $174m estimate by Moelis, while profit before tax was $113.7m versus $111.1m expected.
Profit after tax of $79.6m was below forecast due to tax adjustments, though reported profit was boosted to $186.1m from impairment reversals, observe the analysts. Operating cash flow (OCF) was $190.4m, slightly ahead of expectation.
While earnings were modestly better, much of the upside came from accounting factors rather than operational outperformance, notes Moelis. Tax recognition remains difficult to predict.
The broker retains a Buy rating and a target price of 85c.
This report was published on August 27, 2025.
Target price is $0.85 Current Price is $0.91 Difference: minus $0.06 .
If OBM meets the Moelis target it will return approximately minus 7% .
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.22.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 9.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.29.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PDN PALADIN ENERGY LIMITED
Uranium - Overnight Price: $8.02
rates ((PDN)) as (1) -
Canaccord Genuity gives a pass mark to Paladin Energy's FY25 result, given the scale of transformation, with ramp-up at Langer Heinrich mine, Fission acquisition completion, and setbacks.
FY25 revenue was in line with consensus, though higher than the broker's forecast on accounting of loan repayment. Cost of sales was in line, and attributable net profit was broadly in line.
The company provided an update on Patterson Lake South, which saw a lift in cash cost and initial capex. The broker's forecasts incorporate a buffer over that in terms of first production, opex and capex.
Buy. Target rises to $13.05 from $12.60.
This report was published on August 29, 2025.
Target price is $13.05 Current Price is $8.02 Difference: $5.03
If PDN meets the Canaccord Genuity target it will return approximately 63% .
Current consensus price target is $8.73, suggesting upside of 10.6%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 17.36 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 46.19.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 58.9.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 9.77 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 82.12.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 65.6, implying annual growth of 389.6%.
Current consensus DPS estimate is 9.0, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 12.0.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PFP PROPEL FUNERAL PARTNERS LIMITED
Consumer Products & Services - Overnight Price: $5.05
rates ((PFP)) as (1) -
FY25 results for Propel Funeral Partners exceeded guidance, with revenue of $225.8m above the $220-225m range and up 8% year-on-year, observes Moelis. Earnings (EBITDA) of $56.2m also beat the $54-56m range, with a margin of 24.9%.
Funeral volumes rose 4.4% to 22,602, while organic volumes contracted -1%, less than expected, and comparable average revenue per funeral (ARPF) grew 2.3%. Net leverage was 2.1 times, well within the 5.0 times covenant limit, highlights the analyst.
Recent industry data show death volumes strengthening into mid-2025, supporting a more encouraging outlook for organic volume growth, the broker suggests.
Positively, July revenue of more than $21.5m reflected seasonally stronger funeral numbers, ARPF growth of 2.7%, and contributions from acquisitions, explains the analyst.
Demographic tailwinds from FY28-30 are expected to enhance organic volume growth, while acquisitions of around -$30m per year are assumed by the broker for FY26 and FY27.
Moelis maintains a Buy rating. Target $5.81.
This report was published on August 26, 2025.
Target price is $5.81 Current Price is $5.05 Difference: $0.76
If PFP meets the Moelis target it will return approximately 15% .
Current consensus price target is $5.75, suggesting upside of 14.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 14.40 cents and EPS of 17.20 cents.
At the last closing share price the estimated dividend yield is 2.85%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 29.36.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.1, implying annual growth of 15.6%.
Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 29.4.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 16.40 cents and EPS of 19.60 cents.
At the last closing share price the estimated dividend yield is 3.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.77.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 18.7, implying annual growth of 9.4%.
Current consensus DPS estimate is 15.5, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 26.9.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PRU PERSEUS MINING LIMITED
Gold & Silver - Overnight Price: $4.11
rates ((PRU)) as (1) -
Perseus Mining's FY25 result was an overall beat vs Canaccord Genuity's forecasts, with net profit slightly higher and a final dividend of 7.5c compared with its estimate of 5c.
The company extended $100m share buyback, encouraged by cash balance of US$752m, excluding over US$100m in bullion and $168m in investments.
The broker expects stronger cash flow over FY26-27, and sees the company well-placed to pursue growth opportunities. FY26 production guidance is 400-440koz at US$1,460-1,620/oz cost, and the broker's estimate is 417koz at US$1,474/oz cost.
Buy. Target unchanged at $5.80.
This report was published on August 28, 2025.
Target price is $5.80 Current Price is $4.11 Difference: $1.69
If PRU meets the Canaccord Genuity target it will return approximately 41% .
Current consensus price target is $4.11, suggesting downside of -1.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 6.20 cents and EPS of 49.61 cents.
At the last closing share price the estimated dividend yield is 1.51%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.29.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 33.9, implying annual growth of N/A.
Current consensus DPS estimate is 9.7, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 12.3.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 6.20 cents and EPS of 48.06 cents.
At the last closing share price the estimated dividend yield is 1.51%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.55.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 29.4, implying annual growth of -13.3%.
Current consensus DPS estimate is 6.7, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 14.1.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
RMD RESMED INC
Medical Equipment & Devices - Overnight Price: $41.88
rates ((RMD)) as (1) -
Following a full review of ResMed's FY25 results, Wilsons lifted FY26-27 sales forecasts by 1.6%. EPS forecast for FY26 lifted by 7.8% and FY27 by 8.8%.
Overweight. Target rises to $50.00 from $43.50.
In early impressions, the broker commented:
4Q25 revenue and EPS beat its forecasts by 3% and 4%, respectively. Net profit also beat its estimate by 4% while cash flow rose 22% to US$539m.
Gross margin was 60.8% in 4Q, improving 230bps y/y, and the FY26 guidance was for further increase to 61-63%.
The broker believes there's scope for even higher gross margin of 63-64% over the forecast period on manufacturing and distribution efficiencies.
This report was published on August 4, 2025.
Target price is $50.00 Current Price is $41.88 Difference: $8.12
If RMD meets the Wilsons target it will return approximately 19% .
Current consensus price target is $48.57, suggesting upside of 16.5%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 37.98 cents and EPS of 170.05 cents.
At the last closing share price the estimated dividend yield is 0.91%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 24.63.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 169.8, implying annual growth of N/A.
Current consensus DPS estimate is 36.9, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 24.6.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 40.61 cents and EPS of 192.22 cents.
At the last closing share price the estimated dividend yield is 0.97%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.79.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 188.2, implying annual growth of 10.8%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 22.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SCG SCENTRE GROUP
REITs - Overnight Price: $4.06
rates ((SCG)) as (2) -
Scentre Group remains an attractive proposition, according to Jarden, with an expected three-year compound growth rate in funds from operations of around 6.4% and a good risk profile from a portfolio construction angle.
The outlook for the retail sector is positive, which is expected to transpose to good trading conditions for the group's retail tenants, as evidenced by occupancy up 10bps to 99.7%.
Management is recycling assets, including the sale of a 25% stake in Chermside for $683m on a yield of 5%.
No change to Overweight rating. Target rises to $4.45 from $4.25.
This report was published on August 26, 2025.
Target price is $4.45 Current Price is $4.06 Difference: $0.39
If SCG meets the Jarden target it will return approximately 10% .
Current consensus price target is $4.04, suggesting upside of 0.3%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 17.70 cents and EPS of 22.80 cents.
At the last closing share price the estimated dividend yield is 4.36%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.81.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.6, implying annual growth of 11.7%.
Current consensus DPS estimate is 17.7, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 17.8.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 18.10 cents and EPS of 23.90 cents.
At the last closing share price the estimated dividend yield is 4.46%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.99.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.2, implying annual growth of 7.1%.
Current consensus DPS estimate is 18.4, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 16.7.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SDV SCIDEV LIMITED
Industrial Sector Contractors & Engineers - Overnight Price: $0.32
rates ((SDV)) as (1) -
SciDev's FY25 revenue met Canaccord Genuity's forecast but EBITDA was a slight miss. Operating expenses were higher than expected, though some of them related to costs incurred in anticipation of an earnings upswing.
The outlook commentary was upbeat, with FY26 revenue guidance of $120–140m, up 26% at midpoint. The broker also highlights a leaner cost base and improving operating leverage.
Structural regulatory and environmental tailwinds and acquisitive growth appetite also add to the positive thesis.
Buy. Target unchanged at 60c.
This report was published on August 28, 2025.
Target price is $0.60 Current Price is $0.32 Difference: $0.28
If SDV meets the Canaccord Genuity target it will return approximately 87% .
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.91.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.00.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SFR SANDFIRE RESOURCES LIMITED
Copper - Overnight Price: $12.36
rates ((SFR)) as (3) -
Sandfire Resources' FY25 net profit of US$90m missed Canaccord Genuity's and the consensus forecasts on higher net finance and income tax expenses. Free cash flow was ahead on strong contributions from Matsa and Motheo.
Revenue and EBITDA were pre-reported. No dividend was declared in line with expectations.
The company provided operating cost guidance with 10% increase expected across both operations. The broker expects Motheo costs to rise by 10% in FY26 and Matsa's to be flat in EUR terms, but 10% higher in USD terms.
Target rises to $12.50 from $12.00. Rating downgraded to Hold from Buy.
This report was published on August 28, 2025.
Target price is $12.50 Current Price is $12.36 Difference: $0.14
If SFR meets the Canaccord Genuity target it will return approximately 1% .
Current consensus price target is $12.00, suggesting downside of -3.4%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 15.50 cents and EPS of 74.41 cents.
At the last closing share price the estimated dividend yield is 1.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.61.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 65.9, implying annual growth of N/A.
Current consensus DPS estimate is 7.7, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 18.8.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 15.50 cents and EPS of 105.41 cents.
At the last closing share price the estimated dividend yield is 1.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.73.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 81.5, implying annual growth of 23.7%.
Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 15.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SHL SONIC HEALTHCARE LIMITED
Healthcare services - Overnight Price: $23.75
rates ((SHL)) as (1) -
Wilsons revised forex estimates in its forecasts for Sonic Healthcare, resulting in revisions to forecasts.
The AUD/USD exchange rate is assumed at 0.64, AUD/EUR at 0.55, AUD/GBP 0.48, AUD/CHF 0.52 and AUD/NZD 1.10.
The revisions resulted in a 3% lift to FY26 group revenue and a 4% rise to EPS. For FY26, the group revenue is unchanged, but EPS is trimmed by -1%.
Overweight. Target unchanged at $29.
This report was published on September 1, 2025.
Target price is $29.00 Current Price is $23.75 Difference: $5.25
If SHL meets the Wilsons target it will return approximately 22% .
Current consensus price target is $28.30, suggesting upside of 23.2%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 110.00 cents and EPS of 119.00 cents.
At the last closing share price the estimated dividend yield is 4.63%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.96.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 120.9, implying annual growth of 13.0%.
Current consensus DPS estimate is 109.2, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 19.0.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 112.00 cents and EPS of 127.00 cents.
At the last closing share price the estimated dividend yield is 4.72%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.70.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 133.6, implying annual growth of 10.5%.
Current consensus DPS estimate is 109.0, implying a prospective dividend yield of 4.7%.
Current consensus EPS estimate suggests the PER is 17.2.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SKS SKS TECHNOLOGIES GROUP LIMITED
Technology - Overnight Price: $2.76
rates ((SKS)) as (1) -
Having previously disclosed key FY25 numbers, Wilsons notes the focus of SKS Technologies' FY25 result was guidance, outlook and pipeline.
The FY26 revenue guidance of $300m was in line with the broker's forecast and slightly above consensus. Work in hand was $200m, covering 67% of the FY26 guidance.
The company flagged significant and accelerating growth forecasts in the data centre sector, driving rapidly accelerating pipeline growth. The broker estimates FY26 revenue to rise 18% y/y to $310m, with a further 11% increase in FY27.
Overweight. Target rises to $3.14 from $2.91.
This report was published on August 27, 2025.
Target price is $3.14 Current Price is $2.76 Difference: $0.38
If SKS meets the Wilsons target it will return approximately 14% .
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 7.40 cents and EPS of 16.50 cents.
At the last closing share price the estimated dividend yield is 2.68%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.73.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 8.40 cents and EPS of 18.70 cents.
At the last closing share price the estimated dividend yield is 3.04%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.76.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SLX SILEX SYSTEMS LIMITED
Uranium - Overnight Price: $4.05
rates ((SLX)) as (1) -
After a period of research restriction, Canaccord Genuity has a Speculative Buy rating on Silex Systems and a target price of $6.64.
The broker notes the company remains on track to achieve TRL-6 by year-end (a key technical milestone) and has been invited to bid for up to US$900m in DOE Task Order 2 (TO2) funding under the US Low-Enriched Uranium program.
Commentary suggests the company is strategically well-positioned with a strong balance sheet of $210m cash following recent capital raising amid increasing urgency from the US to secure domestic nuclear fuel supply chains.
This report was published on August 28, 2025.
Target price is $6.64 Current Price is $4.05 Difference: $2.59
If SLX meets the Canaccord Genuity target it will return approximately 64% .
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.17 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 186.64.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 4.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 90.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SOM SOMNOMED LIMITED
Medical Equipment & Devices - Overnight Price: $0.74
rates ((SOM)) as (1) -
Wilsons describes SomnoMed's FY25 result as a structural turnaround with proof of sustainable profitability, robust operating cash flow, and clear momentum in its core US and European businesses.
FY25 sales in the US rose 31% y/y, falling marginally short of the broker's forecast. Europe sales rose 17%, beating the broker's forecast while APAC fell short, despite 10% rise.
FY26 revenue and EBITDA guidance were higher than the broker's estimate, with the company on track for 10% EBITDA margin in FY27.
Overweight. Target rises to $1.00 from $0.80.
This report was published on August 29, 2025.
Target price is $1.00 Current Price is $0.74 Difference: $0.26
If SOM meets the Wilsons target it will return approximately 35% .
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 67.27.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 49.33.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $14.31
rates ((TLX)) as (1) -
Telix Pharmaceuticals received a complete response letter from US FDA for ZIRCAIX related to chemistry, manufacturing and controls. Specifically, it requires demonstrating the product matches what was tested in Phase III.
Wilsons notes the company is seeking a Type A meeting as soon as possible, but such timelines are highly uncertain. As a result, the broker is now assuming a 12-month delay to commercialisation.
FY26 revenue forecast is trimmed by -12% and FY27 by -7%. Overweight. Target lowered to $27.33 from $30.00.
This report was published on August 29, 2025.
Target price is $27.33 Current Price is $14.31 Difference: $13.02
If TLX meets the Wilsons target it will return approximately 91% .
The company's fiscal year ends in December.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 13.33 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 107.34.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 24.96 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 57.34.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TYR TYRO PAYMENTS LIMITED
Business & Consumer Credit - Overnight Price: $1.26
rates ((TYR)) as (1) -
Wilsons highlights Tyro Payments' FY25 EBITDA beat guidance and consensus when adjusted for the -$2.5m one-off non-lending loss.
Total transaction value was flat y/y at $43bn, in line with the broker's forecast, but masked growth in 2H in hospitality and retail. FY26 gross profit guidance is for $230-240m.
The broker reckons the guidance is highly conservative, with early signs of recovery in consumer spending and reduced merchant churn as rate cuts begin to flow through.
Strong cost control, new vertical contributions, and optionality from two-way M&A underpin the Overweight rating.
Target lifted to $1.40 from $1.15.
This report was published on August 27, 2025.
Target price is $1.40 Current Price is $1.26 Difference: $0.14
If TYR meets the Wilsons target it will return approximately 11% .
Current consensus price target is $1.38, suggesting upside of 7.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 28.64.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 4.1, implying annual growth of 20.9%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 31.2.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 0.00 cents and EPS of 5.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 23.33.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 4.6, implying annual growth of 12.2%.
Current consensus DPS estimate is 0.5, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 27.8.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
WEB WEB TRAVEL GROUP LIMITED
Travel, Leisure & Tourism - Overnight Price: $4.30
rates ((WEB)) as (2) -
Web Travel's AGM produced a softer-than-anticipated update, with TTV growth weakening since the FY25 result due to forex headwinds of -4% and challenges in the Middle East. TTV for FY26 is expected to be in the mid-high teens, at least $3.1bn versus consensus at $3.2bn.
There were no changes to the long-term TTV target of $10bn. News flow is expected to improve from here, with indications the global travel market is bottoming out.
Jarden lowers its net profit after tax forecasts by -9% for FY26 and -3% for FY27.
Overweight retained. Target slips to $5.30 from $5.40.
This report was published on August 26, 2025.
Target price is $5.30 Current Price is $4.30 Difference: $1
If WEB meets the Jarden target it will return approximately 23% .
Current consensus price target is $5.98, suggesting upside of 39.8%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 9.00 cents and EPS of 26.00 cents.
At the last closing share price the estimated dividend yield is 2.09%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.54.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.4, implying annual growth of -53.2%.
Current consensus DPS estimate is 1.3, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 17.5.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 10.00 cents and EPS of 31.70 cents.
At the last closing share price the estimated dividend yield is 2.33%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.56.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 32.2, implying annual growth of 32.0%.
Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 13.3.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
WGX WESTGOLD RESOURCES LIMITED
Gold & Silver - Overnight Price: $3.68
rates ((WGX)) as (1) -
Westgold Resources' FY25 revenue met Canaccord Genuity's forecast but net profit was a big miss due to higher depreciation. Final unfranked dividend of 3c was higher than the broker's estimate of 1.9c and the consensus of 1.5c.
The company ended FY25 with cash/bullion of $336m, $50m in drawn debt and $250m in available facilities. Share buyback of up to 5% of shares was announced.
The recently provided production guidance was retained, and capex and exploration guidance were unchanged.
The broker lifted FY26-27 cost forecasts by 2% and 3%, respectively, to allow for a more conservative estimate. Depreciation forecasts for FY26-28 are also raised.
Buy. Target trimmed to $5.10 from $5.25.
This report was published on August 28, 2025.
Target price is $5.10 Current Price is $3.68 Difference: $1.42
If WGX meets the Canaccord Genuity target it will return approximately 39% .
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 4.00 cents and EPS of 44.00 cents.
At the last closing share price the estimated dividend yield is 1.09%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.36.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 7.00 cents and EPS of 57.00 cents.
At the last closing share price the estimated dividend yield is 1.90%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.46.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
